-
Mashup Score: 0Mejoras en la supervivencia global del mieloma: ¿de dónde proviene este tiempo adicional? - 23 day(s) ago
¡Los mejores tratamientos mejoran la supervivencia!
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Rafael Fonseca, M.D.1
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
An amazing to to visualize the present and the future! (Pun intended) - the future is in spatial computing and Apple Vision Pro leads! A link to a blog I previously wrote about this. tremendous work by @sharphealthcare and @TommyKornMD @Apple https://t.co/KbhmCyoGR2 https://t.co/nnYZho3YE7
-
-
Mashup Score: 14MIDAS touch is golden! - 1 month(s) ago
It is time to add quads including carfilzomib as the preferred proteasome inhibitor in the front-line therapy for multiple myeloma (MM)
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
The MIDAS touch (isa-KRD) Sets the stage for optimal induction Rx of myeloma. KEY POINTS 1) Carfilzomib should a preferred drug for frontline treatment 2) Who says it should always be 3 cycles before SCT 3) Much safer regarding neuropathy #mmsm https://t.co/w8cktWWvQw https://t.co/bQteNRAEvu https://t.co/zEshJA6ebt
-
-
Mashup Score: 3
Better treatments improve survival!
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
And here’s my original Substack post https://t.co/HXOXLsgWkZ
-
-
Mashup Score: 2Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma - 9 month(s) ago
A Komodo Real World Evidence analysis
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
A quick reminder that CART induced T cell NHL are very rare and it should not be assumed they are always casually linked. Of all the things patients have to consider this is at best minimal/trivial, possibly a possible distraction. https://t.co/WYNwDs3aja Nature story… https://t.co/tQZetOScoo https://t.co/EgRRi0sTDT
-
-
Mashup Score: 0
Better treatments improve survival!
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
Where does this extra survival time come if the clinical trials do not show improved overall survival? https://t.co/Mp4yqKu1Tg https://t.co/uUnqKm9fmN
-
-
Mashup Score: 3QALY-fying the value of life - 1 year(s) ago
Questions about the ethics of QALYs
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
I just heard about a vote tomorrow aiming to extend the prohibition of quality-adjusted life years (QALY) that devalues lives based on age or disability. I thought to repost my write-up from 2016. https://t.co/HLWYovuErM @HouseCommerce @cathymcmorris @oncotastic #QALY… https://t.co/jRmSeoZLb1 https://t.co/MrclJOeES0
-
-
Mashup Score: 6Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma - 1 year(s) ago
A Komodo Real World Evidence analysis
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
These data is presented in greater detail in this Substack with the primary author being Dr @GKaurMD and the other authors are @ARosenthalDO, @erivaserra and @Chhabra_mayo https://t.co/RFgJAWhb0U 8/xl #mmSM #lymSM
-
-
Mashup Score: 6Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma - 1 year(s) ago
A Komodo Real World Evidence analysis
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
These data is presented in greater detail in this Substack with the primary author being Dr @GKaurMD and the other authors are @ARosenthalDO, @erivaserra and @Chhabra_mayo https://t.co/RFgJAWhb0U 8/xl #mmSM #lymSM
-
-
Mashup Score: 6Incidence or T cell lymphoma in patients diagnosed with multiple myeloma or diffuse large B-cell lymphoma - 1 year(s) ago
A Komodo Real World Evidence analysis
Source: rafaelfonseca.substack.comCategories: General Medicine News, Hem/OncsTweet-
These data is presented in greater detail in this Substack with the primary author being Dr @GKaurMD and the other authors are @ARosenthalDO, @erivaserra and @Chhabra_mayo https://t.co/RFgJAWhb0U 8/xl #mmSM #lymSM
-
Mejoras en la supervivencia global del mieloma: ¿de dónde proviene este tiempo adicional? #mmsm https://t.co/hFqrJvzan9 https://t.co/H9poG7UhB6